Opendata, web and dolomites


Innovative Glycan-based analysis for Cancer diagnostics

Total Cost €


EC-Contrib. €






 GlyCan project word cloud

Explore the words cloud of the GlyCan project. It provides you a very rough idea of what is the project "GlyCan" about.

diagnostic    scientific    prior    sending    outcome    quantify    false    undergo    tkac    rate    6m    co    simplicity    confirm    clinically    dna    team    annually    competitors    75    patients    home    ing    jan    examinations    lacks    advisors    founder    needless    diagnostics    commercial    accurately    grant    detect    centres    deaths    homes    advantage    kit    market    launched    circulating    biomolecules    mrna    antigen    burden    cso    business    psa    dr    366k    clinics    screening    biopsy    owned    innovative    patent    opinion    assay    epo    b2b    biopsies    societal    prostate    74    worldwide    glycanostics    blood    suspicious    representing    core    b2c    granted    sick    95    covered    company    preliminary    quantifying    pca    pain    cancer    competitive    biomarker    digital    instead    hospital    examination    rectal    protein    accuracy    invasive    2nd    check    311532    serum    combined    members    dre    discriminates    erc    consists    healthy    positive    glycan    mistreatment    dx    throughput    biomarkers    economic    proteins   

Project "GlyCan" data sheet

The following table provides information about the project.


Organization address
postcode: 845 38
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Slovakia [SK]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-08-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLYCANOSTICS SRO SK (BRATISLAVA) coordinator 50˙000.00


 Project objective

Worldwide, there are 1.6M new prostate cancer (PCa) cases with 366k deaths annually. Novel PCa biomarkers are needed since the best current PCa biomarker (prostate specific antigen (PSA)) lacks PCa diagnostic accuracy often resulting in mistreatment of PCa patients. The false-positive rate of PSA in blood serum is ~75%. PSA test is applied together with digital rectal examination (DRE) for preliminary screening. If the combined results are suspicious, the patients undergo a biopsy to confirm PCa. Yet, there are 74% of needless biopsies representing a significant pain for PCa patients and societal/economic burden.

Based on a great commercial outcome from the ERC grant (311532) granted to Dr. Jan Tkac (co-founder/CSO of Glycanostics), the company has developed an innovative, non-invasive, early PCa diagnostics using blood serum. Instead of quantifying PSA, the innovative PCa diagnostic assay detect glycan changes on PSA protein (it discriminates between “healthy” PSA and “sick” PSA and accurately quantify the clinically relevant “sick” PSA). The technology is covered by two EPO patent applications owned by the company. The PCa diagnostic test with 95% accuracy will be applied as a 2nd opinion test in case of suspicious results from PSA & DRE examinations prior sending to a biopsy. PCa DX kit will be launched for clinics/hospital & cancer centres (B2B) and Prostate check home test for user-friendly application at homes (B2C).

Our PCa diagnostic technology is unique compared to our competitors focusing on analysis of other complex biomolecules such as a level of proteins, mRNA and circulating DNA. Moreover, we have competitive advantage over competitors in terms of cost per sample, assay accuracy, simplicity of the assay enabling the home testing and high-throughput.

Glycanostics consists of 7 core team members, 4 business and 4 scientific advisors making a great and highly experienced team that will bring these innovative PCa early diagnostic products to the market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLYCAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLYCAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

Presque (2019)

Smart Nursing Bra

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More